These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 16601877)

  • 1. The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease.
    Kalliokoski RJ; Kantola I; Kalliokoski KK; Engblom E; Sundell J; Hannukainen JC; Janatuinen T; Raitakari OT; Knuuti J; Penttinen M; Viikari J; Nuutila P
    J Inherit Metab Dis; 2006 Feb; 29(1):112-8. PubMed ID: 16601877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease.
    Kalliokoski RJ; Kalliokoski KK; Sundell J; Engblom E; Penttinen M; Kantola I; Raitakari OT; Knuuti J; Nuutila P
    J Inherit Metab Dis; 2005; 28(4):563-73. PubMed ID: 15902560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myocardial Storage, Inflammation, and Cardiac Phenotype in Fabry Disease After One Year of Enzyme Replacement Therapy.
    Nordin S; Kozor R; Vijapurapu R; Augusto JB; Knott KD; Captur G; Treibel TA; Ramaswami U; Tchan M; Geberhiwot T; Steeds RP; Hughes DA; Moon JC
    Circ Cardiovasc Imaging; 2019 Dec; 12(12):e009430. PubMed ID: 31826677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters.
    Koskenvuo JW; Hartiala JJ; Nuutila P; Kalliokoski R; Viikari JS; Engblom E; Penttinen M; Knuuti J; Mononen I; Kantola IM
    J Inherit Metab Dis; 2008 Jun; 31(3):432-41. PubMed ID: 18509742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study.
    Mignani R; Panichi V; Giudicissi A; Taccola D; Boscaro F; Feletti C; Moneti G; Cagnoli L
    Kidney Int; 2004 Apr; 65(4):1381-5. PubMed ID: 15086478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A detailed pathologic examination of heart tissue from three older patients with Anderson-Fabry disease on enzyme replacement therapy.
    Sheppard MN; Cane P; Florio R; Kavantzas N; Close L; Shah J; Lee P; Elliott P
    Cardiovasc Pathol; 2010; 19(5):293-301. PubMed ID: 19631563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.
    Sasa H; Nagao M; Kino K
    Mol Genet Metab; 2019 Apr; 126(4):448-459. PubMed ID: 30803893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Fabry disease in Spain: first analysis of the response to enzyme replacement therapy].
    Rivera Gallego A; López Rodríguez M; Barbado Hernández FJ; Barba Romero MA; García de Lorenzo Y Mateos A; Pintos Morelle G;
    Med Clin (Barc); 2006 Oct; 127(13):481-4. PubMed ID: 17043001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
    Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L
    Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study.
    Imbriaco M; Pisani A; Spinelli L; Cuocolo A; Messalli G; Capuano E; Marmo M; Liuzzi R; Visciano B; Cianciaruso B; Salvatore M
    Heart; 2009 Jul; 95(13):1103-7. PubMed ID: 19372091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring enzyme replacement therapy in Fabry disease--role of urine globotriaosylceramide.
    Whitfield PD; Calvin J; Hogg S; O'Driscoll E; Halsall D; Burling K; Maguire G; Wright N; Cox TM; Meikle PJ; Deegan PB
    J Inherit Metab Dis; 2005; 28(1):21-33. PubMed ID: 15702403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
    Tsuboi K; Yamamoto H
    BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study.
    Weidemann F; Breunig F; Beer M; Sandstede J; Turschner O; Voelker W; Ertl G; Knoll A; Wanner C; Strotmann JM
    Circulation; 2003 Sep; 108(11):1299-301. PubMed ID: 12952834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in cleavage of globotriaosylceramide and its derivatives accumulated in organs of young Fabry mice following enzyme replacement therapy.
    Kodama T; Tsukimura T; Kawashima I; Sato A; Sakuraba H; Togawa T
    Mol Genet Metab; 2017; 120(1-2):116-120. PubMed ID: 27756537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications.
    Weidemann F; Niemann M; Störk S; Breunig F; Beer M; Sommer C; Herrmann S; Ertl G; Wanner C
    J Intern Med; 2013 Oct; 274(4):331-41. PubMed ID: 23586858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a chemically modified plant cell culture expressed human α-Galactosidase-A enzyme for treatment of Fabry disease.
    Kizhner T; Azulay Y; Hainrichson M; Tekoah Y; Arvatz G; Shulman A; Ruderfer I; Aviezer D; Shaaltiel Y
    Mol Genet Metab; 2015 Feb; 114(2):259-67. PubMed ID: 25155442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa.
    Lin HY; Huang YH; Liao HC; Liu HC; Hsu TR; Shen CI; Li ST; Li CF; Lee LH; Lee PC; Huang CK; Chiang CC; Lin SP; Niu DM
    J Chin Med Assoc; 2014 Apr; 77(4):190-7. PubMed ID: 24388678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme replacement therapy in Fabry disease: influence on cardiac manifestations.
    Caballero L; Climent V; Hernández-Romero D; Quintanilla MA; de la Morena G; Marín F
    Curr Med Chem; 2010; 17(16):1679-89. PubMed ID: 20345350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.
    Wang RY; Abe JT; Cohen AH; Wilcox WR
    J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S369-74. PubMed ID: 18937048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis.
    Kampmann C; Linhart A; Devereux RB; Schiffmann R
    Clin Ther; 2009 Sep; 31(9):1966-76. PubMed ID: 19843486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.